

CURRICULUM VITAE**Name:** G Greg Wang, Ph.D.**Address:** 450 West Drive, CB 7295,
UNC Lineberger Cancer Center, Room 31-327
Chapel Hill, NC 27599-7295
Office tel: 919-966-5952; Lab tel: 919-966-5953; Fax: 919-966-9673
Email: greg_wang@med.unc.edu
Website: www.gregwanglab.com**EDUCATION**

1993 - 1997	Fudan University	B.S.	Biochemistry
1997 - 2000	Fudan University Medical Center	M.S.	Pathogenic and Cancer Biology
2000 - 2006	University of California at San Diego	Ph.D.	Biomedical Sciences (mentor: Mark P. Kamps; co-mentor: Christopher K Glass)
2007 - 2011	Rockefeller University	Postdoctoral fellow	Chromatin Biology & Epigenetics (mentor: C. David Allis)

PROFESSIONAL EXPERIENCE

2012 - 2018	University of North Carolina (UNC) at Chapel Hill	Assistant Professor	Biochemistry and Biophysics
2018 - present	UNC at Chapel Hill	Associate Professor (tenured)	Biochemistry and Biophysics
2012 - present	UNC Lineberger Comprehensive Cancer Center (LCCC)	Member	Cancer Cell Biology
2014 - present	University of North Carolina (UNC) at Chapel Hill	Preceptor	Curriculum in Genetics and Molecular Biology
2014 - present	LCCC of UNC at Chapel Hill	Preceptor	T32: Cancer Epigenetics Training Program (CETP)
2016 - present	LCCC of UNC at Chapel Hill	Preceptor	T32: Integrated Training in Cancer Model Systems (ITCMS)

HONORS AND AWARDS

1993	Merit High School Student, Providence of Jiangsu, China	Ministry of Education, China
------	---	------------------------------

1994 - 1996	People's Fellowship (second prize; merit-based undergraduate scholarship)	Fudan University School of Life Sciences, China
2000	United Scholarship (top prize) for graduate/medical student	Fudan University Medical Center, China
2007	Choh-Hao Li Memorial Fund Scholar (postdoctoral fellowship)	Rockefeller University, New York, NY
2008	Leukemia & Lymphoma Society Postdoc Fellow award	Leukemia & Lymphoma Society
2008	Irvington Institute - Cancer Research Institute Postdoctoral Fellowship (declined)	Irvington Institute and Cancer Research Institute
2010	Howard Temin 'Pathway to Independence' Award in Cancer Research (K99/R00)	NIH/NCI
2012	Martin D. Abeloff MD. V Scholar (top rating)	V Foundation for Cancer Research
2013	Jefferson-Pilot Fellowship in Academic Medicine	UNC School of Medicine
2013	American Society of Hematology (ASH) Scholar in Basic Science	ASH
2014	Janet D. Rowley Medical Research Award	Gabrielle's Angel Foundation for Cancer Research (GAFCR)
2014	Kimmel Scholar	Sidney Kimmel Foundation for Cancer Research
2014	CONquer canCER Now (CONCERN) Award	CONCERN Foundation
2014	DoD Career Development Award	DoD, Peer Reviewed Cancer Research Program (PRCRP)
2016	American Cancer Society (ACS) Scholar	ACS
2017	Gilead Sciences Research Scholar	Gilead Inc. Scholars Program
2018	Leukemia & Lymphoma Society Scholar	LLS
2019	Phillip and Ruth Hettleman Prize for Scholarly and Artistic Achievement	UNC
2019	Yang Family Biomedical Scholar	UNC School of Medicine

MEMBERSHIPS

2004 - present	American Society of Hematology (ASH)
2007 - 2012	New York Academy of Sciences (NYAS)
2014 - present	American Association of Cancer Research (AACR)
2016 - present	American Society for Biochemistry and Molecular Biology (ASBMB)

Bibliography (in reverse chronological order)**KEY PUBLICATIONS** (#, co-correspondence; *, co-first authors)

1. Ren W, Fan H, Grimm SA, Guo Y, Kim JJ, Li L, Petell CJ, Tan XF, Zhang ZM, Coan JP, Yin J, Gao L, Cai L, Detrick B, Çetin B, Wang Y, Cui Q, Strahl BD, Gozani O, Miller KM, O'Leary SE, Wade PA, Patel DJ, **Wang GG**#, Song J#. Direct readout of heterochromatic H3K9me3 regulates DNMT1-mediated maintenance DNA methylation. *PNAS* (in press).
2. Gao L, Emperle M, Guo Y, Grimm SA, Ren W, Adam S, Uryu H, Zhang ZM, Chen D, Yin J, Dukatz M, Anteneh H, Jurkowska RZ, Lu J, Wang Y, Bashtrykov P, Wade PA, **Wang GG**#, Jeltsch A#, Song J#. Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms. *Nat Commun*. 2020 Jul 3;11(1):3355. doi: 10.1038/s41467-020-17109-4.PMID: 32620778
3. Zhang Y, Guo Y, Gough SM, Zhang J, Vann KR, Li K, Cai L, Shi X, Aplan PD, **Wang GG**, Kutateladze TG. Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion. *Nat Commun*. 2020 Jul 3;11(1):3339. doi: 10.1038/s41467-020-17098-4.PMID: 32620764
4. Pi WC, Wang J, Shimada M, Lin JW, Geng H, Lee YL, Lu R, Li D, **Wang GG**, Roeder RG, Chen WY. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. *Blood*. 2020 Jul 2;136(1):11-23. doi: 10.1182/blood.2019003312.PMID: 32276273
5. De Silva D, Zhang Z, Liu Y, Parker JS, Xu C, Cai L, **Wang GG**, Earp HS, Whang YE. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. *Sci Rep*. 2019 Dec 9;9(1):18637. doi: 10.1038/s41598-019-55057-2.
6. Ren W, Lu J, Huang M, Gao L, Li D, **Wang GG**, Song J. Structure and regulation of ZCCHC4 in m6A-methylation of 28S rRNA. *Nat Commun*. 2019 Nov 6;10(1):5042. PMID: 31695039.
7. Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, **Wang GG**#. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. *Blood*. 2019 Aug 5. pii: blood.2019000578.
8. Lamb KN, Bsteh D, Dishman SN, Moussa HF, Fan H, Stuckey JI, Norris JL, Cholensky SH, Li D, Wang J, Sagum C, Stanton BZ, Bedford MT, Pearce KH, Kenakin TP, Kireev DB, **Wang GG**, James LI, Bell O#, Frye SV#. Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. *Cell Chem Biol*. 2019 Aug 14. pii: S2451-9456(19)30244-2.

9. Lu R, Wang J, Ren Z, Yin J, Wang Y, Cai L, **Wang GG**[#]. A model system for studying the DNMT3A hotspot mutation (DNMT3A^{R882}) demonstrates a causal relationship between its dominant-negative effect and leukemogenesis. *Cancer Res.* 2019 Jul 15;79(14):3583-3594.
10. Jie L, Ahn JH, **Wang GG**[#]. Understanding histone H3 lysine 36 methylation and its deregulation in disease. *Cell. & Mol. Life Sciences.* 2019 Aug;76(15):2899-2916. (Invited review for a special issue of "Protein Methylation in Cellular Physiology")
11. Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, **Wang GG**, Gray NS, Cleveland JL, Qi J[#], Tao J[#]. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. *Cancer Cell.* 2019 May 13;35(5):752-766.e9.
12. R-loops: formation, function, and relevance to cell stress. Allison DF, **Wang GG**[#]. *Cell Stress* 2019; 3 (2), 38-47.
13. Cai L, Tsai Y, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS[#], **Wang GG**[#]. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. *Mol Cell.* 2018 Oct 18;72(2):341-354.e6. Epub 2018 Sep 27.
14. Zhang Z*, Lu R*, Wang P, Chen DL, Yu Y, Liu S, Ji D, Gao L, Rothbart SB, Wang YS, **Wang GG**[#], Song J[#]. Structural basis for DNMT3A-mediated de novo DNA methylation. *Nature* 2018 Feb 15;554(7692):387-391. Epub 2018 Feb 7.

With news and views at *Cancer Discovery* February 27 2018 DOI:10.1158/2159-8290.CD-NB2018-020
15. The chromatin remodeler Bptf activates a stemness gene-expression program essential for the maintenance of adult hematopoietic stem cells. Xu B, Cai L, Butler JM, Chen D, Lu X, Allison DF, Lu R, Rafii S, Parker JS, Zheng D, **Wang GG**[#]. *Stem Cell Reports* 2018 Feb 8. pii: S2213-6711(18)30046-8. doi: 10.1016/j.stemcr.2018.01.020. [Epub ahead of print]
16. Lu R, **Wang GG**[#]. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. *Front Oncol.*, 2017 Oct 12; 7:241. PMID: 29075615
17. Lu R, **Wang GG**[#]. Gene enhancer deregulation and epigenetic vulnerability. *Oncoscience.* 2016 Nov; 3(11-12), 299-301.
18. Lu R, Wang P, Parton T, Zhou Y, Chrysovergis K, Rockowitz S, Chen WY, Abdel-Wahab O, Wade PA, Zheng D[#], **Wang GG**[#]. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene expression program and acute leukemia development. *Cancer Cell.* 2016 July 11; 30(1):92-107.

Cover image and News & Views at: *Cancer Cell* 2016; 30(1):9-10 and *Cancer Discovery* 2016; 6(8):815.
19. Wu B, Wang Y, Wang C, **Wang GG**, Wu J, Wan YY[#]. BPTF Is Essential for T Cell Homeostasis and Function. *J Immunol.* 2016 Dec 1; 197(11):4325-4333. PMID: 27799308

20. Zhou Y, Wang L, Vaseghi HR, Liu Z, Lu R, Alimohamadi S, Yin C, Fu JD, **Wang GG**, Liu J, Qian L[#]. Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming. *Cell Stem Cell*. 2016 Mar 3; 18(3):382-95.
21. Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, **Wang GG**, Jiang X, Liu PP, Jin J, Chen J[#]. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. *Cancer Res*. 2016 Feb 1; 76(3):619-29. PMID: 26747896
22. Xu B*, On DM*, Ma A*, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, **Wang GG**[#]. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. *Blood*. 2015 Jan 8; 125(2):346-57. PMID: 25395428. PMCID: PMC4287641.
23. Zhang ZM, Rothbart SB, Allison DF, Cai Q, Harrison JS, Li L, Wang Y, Strahl BD, **Wang GG**, Song J[#]. An Allosteric Interaction Links USP7 to Deubiquitination and Chromatin Targeting of UHRF1. *Cell Rep*. 2015 Sep 1; 12(9):1400-6. PMID: 26299963
24. Xu B, Konze KD, Jin J, **Wang GG**[#]. Targeting EZH2 and PRC2 dependency as novel anti-cancer therapy. *Exp. Hematol*. 2015 Aug; 43(8):698-712. PMID: 26027790
25. **Wang GG**[#], Konze KD, Tao JG[#]. Polycomb Genes, miRNA, and Their Deregulation in B-cell Malignancies. *Blood*. 2015; 125(8):1217-25. PMID: 25568352. PMCID: PMC4335077.
26. Gong H, Qian H, Ertl R, Astle CM, **Wang GG**, Harrison DE, Xu X[#]. Histone modifications change with age, dietary restriction and rapamycin treatment in mouse brain. *Oncotarget*. 2015; 6(18):15882-90. PMID: 26021816. PMCID: PMC4599244
27. Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, **Wang GG**, Meltzer PS, Aplan PD[#]. NUP98-PHF23 is a chromatin modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD domain histone reader function. *Cancer Discovery*. 2014; 4(5):564-77. PMID: 24535671
28. Lu R, **Wang GG**[#]. Tudor: a versatile family of histone methylation readers. *Trends Biochem Sci*. 2013 Nov; 38(11):546-55. PMID: 24035451
29. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, **Wang GG**, Vedadi M, Jin J[#]. An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. *ACS Chem Biol*. 2013; 8(6):1324-34.
30. Cai L*, Rothbart SB*, Lu R*, Xu B, Chen WY, Tripathy A, Rockowitz S, Zheng D, Patel DJ, Allis CD, Strahl BD, Song J[#], **Wang GG**[#]. An H3K36 methylation engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. *Mol Cell*. 2013 Feb 7; 49(3):571-82. PMID: 23273982.
31. Kumar GS, Chang W, Xie T, Patel A, Zhang Y, **Wang GG**, David G, Radhakrishnan I[#]. Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1

subunits of the Rpd3S/Sin3S corepressor complex. *J Mol Biol.* 2012 Sep 28;422(4):519-31. Epub 2012 Jun 21.

32. Milne TA, Kim J, **Wang GG**, Wang Z, Ren X, Basrur V, Ruthenburg AJ, Elenitoba-Johnson K, Patel DJ, Roeder RR and Allis CD[#]. Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the *HOXA9* Locus in Leukemogenesis. *Mol. Cell.* 2010, 25; 38(6):853-63. PMID: 20541448.

33. **Wang GG**, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo J, Patel DJ and Allis CD[#]. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. *Nature.* 2009, 459(7248):847-851. PMID: 20541251.

News & Views at *Nat Rev Cancer* 2009(9):461, *Nat Chem Biol* 2009;5(7):457 & *Science News* 2009,175 (12):11

34. Chi P, Allis CD[#], **Wang GG**[#]. Covalent histone modifications: mis-written, mis-erased and mis-interpreted in human cancers. *Nat Rev Cancer.* 2010,10(7):457-69. PMID: 20574448.

35. Wang Z, Song J, Milne TA, **Wang GG**, Li H, Allis CD, and Patel DJ[#]. Proline Isomerization in MLL1 PHD3-Bromo Cassette Connects H3K4me Readout to Cyp33 and HDAC-Mediated Repression. *Cell.* 2010, 141(7): 1183-94. PMID: 20541251.

36. Ferris AL, Wu X, Hughes CM, Stewart C, Smith SJ, Milne TA, **Wang GG**, Shun MC, Allis CD, Engelman A and Hughes SH[#]. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. *Proc Natl Acad Sci.* 2010,107(7): 3135-40.

37. **Wang GG**[#], Allis CD[#]. Misinterpretation of a histone mark is linked to aberrant stem cells and cancer development. *Cell Cycle.* 2009; 8(13):1982-3. PMID: 19550157

38. Baker LA, Allis CD and **Wang GG**[#]. PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. *Mutat Res.* 2008, 647(1-2): 3-12. PMID: 18682256

39. **Wang GG**, Allis CD[#] and Chi P[#]. Chromatin remodeling and cancer: covalent histone modifications. *Trends Mol Med.* 2007,13(9):363-72. With cover illustration.

40. **Wang GG**, Allis CD[#] and Chi P[#]. Chromatin remodeling and cancer: ATP-dependent chromatin remodeling. *Trends Mol Med.* 2007, 13(9): 373-80.

41. **Wang GG**, Cai L, Pasillas MP and Kamps MP[#]. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. *Nature Cell Biol.* 2007,9(7): 804-812. PMID: 17589499

42. **Wang GG**, Calvo KR, Pasillas MP, Sykes DB, Hacker H and Kamps MP[#]. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. *Nature Methods*, 2006,3(4): 287-93.

News and Views at *Nat Methods* 2006; 3(4): 248 – 249.

43. **Wang GG**, Kamps MP[#]. Survival signaling in HoxA9/Meis1 AML. *Blood.* 2007; 109(9):3619-3620.

44. **Wang GG**, Pasillas MP and Kamps MP[#]. Persistent transactivation by Meis1 replaces Hox function in myeloid leukemogenesis models: evidence for co-occupancy of Meis1-Pbx and

Hox-Pbx complexes on promoters of leukemia-associated genes. *Mol Cell Biol.* 2007, 26(10): 3902-16. PMID: 16648484

45. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, **Wang GG**, Kamps MP, Raz E, Wagner H, Hacker G, Mann M and Karin M[#]. Specificity in Toll-like receptor signaling through distinct effector functions of TRAF3 and TRAF6. *Nature.* 2006, 439(7073):204-7. PMID: 16306937
46. **Wang GG**, Pasillas MP and Kamps MP[#]. Meis1 programs transcription of *FLT3* and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. *Blood.* 2005, 106(1):254-64. PMID: 15755900

Editors' views at *Blood* 2005; 106(1):6-7.

47. **Wang G**, Zhao Y, Liu X, Wang L, Wu C, Zhang W, Liu W, Zhang P, Cong W, Zhu Y, Zhang L, Chen S, Wan D, Zhao X, Huang W and Gu JR[#]. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. *Genes Chromosomes Cancer.* 2001, 31(3):221-7. PMID: 11391792
48. **Wang G**, Huang CH, Zhao Y, Cai L, Wang Y, Xiu SJ, Jiang ZW, Yang S, Zhao T, Huang W and Gu JR[#]. Genetic aberration in primary hepatocellular carcinoma: correlation between p53 gene mutation and loss-of-heterozygosity on chromosome 16q21-q23 and 9p21-p23. *Cell Res.* 2000, 10(4): 311-23. PMID: 11191353

SERVICE TO GOVERNMENT AND PROFESSIONAL ORGANIZATIONS

Editorial board (Journal)

2017 - present	Cell Stress	Academic Editor
2018 - present	Cancer Epigenetics	Editorial Board

Grant review panel

2016 - present	American Cancer Society (ACS) Peer Review Committee on DNA Mechanisms in Cancer	Regular review panel member 2016-2020
2019 - now	NIH Cancer Molecular Pathobiology (CAMP) study section	Regular member of NIH study section

Ad hoc review panels for funding agents in USA:

NIH Cancer Genetics (CG) study section (2015 Oct); NIH Cancer Molecular Pathobiology (CAMP) study section (2017-2018); NIH Special Emphasis Panel/Scientific Review Group 2019/05 ZRG1 OBT-H (02) M (2019 April); University Cancer Research Fund (UCRF) Stimulus Grants review panel, UNC (2016, 2017)

Ad hoc review panels for funding agents outside of USA:

Cancer Research Wales, UK (2016); European Research Council (ERC, 2013); French National Cancer Institute/Institut National du Cancer (INCa), France (2018, 2019); Kay Kendall Leukemia Fund, UK (2009), Medical Research Council (MRC), UK (2015,

2018); Natural Sciences and Engineering Research Council of Canada (NSERC), Canada (2017, 2018); Worldwide Cancer Research, UK (2019)

Symposium organizer

2019	The 43 rd Annual Lineberger Symposium on “Dysregulated Signaling Pathways in Cancer: Insights into Novel Mechanisms and Therapeutic Approaches”, Chapel Hill, NC	Symposium co-organizer
2018	Abcam-sponsored NC Symposium on “epigenetics, chromatin structure and epitranscriptomics”, RTP, NC	Symposium co-organizer
2015	Abcam-sponsored NC Symposium on “Epigenetic regulation of stem cells & aging”, Chapel Hill, NC	Symposium co-organizer
2014	The 38th Annual Lineberger Symposium on “Epigenetics & Cancer”, Chapel Hill, NC	Symposium co-organizer
2014	56th Annual Meeting of the American Society of Hematology (ASH), San Francisco, CA	Abstract selection reviewer

SERVICE TO PROFESSIONAL PUBLICATIONS

Ad hoc referee for peer-reviewed manuscripts. Since 2012, journals include:

ACS Chemical Biology, Biochemistry, Biomolecules, Blood, British Journal of Cancer, Cancer Research, Cancer Science, Cell, Cellular & Molecular Life Sciences, Cell Reports, Cell Research, Chemistry & Biology, Current Biology, eLife, Experimental Cell Research, Genes, Genome Biology, Haematologica, Leukemia, Journal of Cell Biology, Journal of Clinical Investigation, Molecular Cell, Nature, Nature Chemical Biology, Nature Communications, PLOS Biology, PLOS Genetics, Trends in Genetics, Science, Science Advances, Scientific Reports, Structure

SEMINARS & SPEECHES (in reverse chronological order)

INVITED PRESENTATIONS - INTERNATIONAL & NATIONAL

Pending 2021	Invited Speech, Epigenetic Mechanisms and Advances in Chromatin Biology, 2020 International Chemical Congress of Pacific Basin Societies (PAC CHEM), Honolulu, Hawaii, USA
11/8-13/2020	Invited Speech, EpiCypher 2020 Conference in Biological and Clinical Frontiers in Epigenetics, Playa del Carmen, Mexico
7/8-12/2019	Invited Talk, 2019 Telluride Symposium on Epigenetic Mechanisms, Telluride, CO, USA

- 4/29/2019 Talk (served as symposium co-organizer), 43rd Annual Lineberger Symposium on “Dysregulated Signaling Pathways in Cancer: Insights into Novel Mechanisms and Therapeutic Approaches”, Chapel Hill, NC, USA
- 11/07/2018 Invited Talk, the 2018 EpiCypher Conference on Biological and Clinical Frontiers in Epigenetics, Nassau, Bahamas
- 6/20/2018 Talk Selected from Abstracts, the 2018 FASEB Conference on “Biological Methylation: Fundamental Mechanisms in Human Health and Disease”, Florence, Italy
- 5/7/2018 Invited Talk (Lightning Round), the Twelfth International Workshop on “Molecular Aspects of Myeloid Stem Cell Development and Leukemia”, Cincinnati, OH, USA
- 4/23/2017 Invited Talk (Spotlight Session), the 17th Annual Meeting of the American Society for Biochemistry and Molecular Biology (ASBMB), Chicago, IL, USA
- 11/15/2016 Invited Talk, the 7th Annual Medical Symposium of Gabrielle's Angel Foundation for Cancer Research (GAFRC), New York City, NY, USA
- 4/21/2016 Invited Talk, the 2016 EpiCypher Conference of Biological and Clinical Frontiers in Epigenetics, San Juan, Puerto Rico
- 2/9/2015 Invited Talk, the 2015 Workshop on “Epigenetic Inhibitors: Target Validation through Chemical Biology”, Toronto, Canada
- 7/7/2014 Invited Talk, the 2014 FASEB meeting on “Methylation and Epigenetics”, Nassau, Bahamas
- 4/21/2014 Invited Talk, the 38th Annual Lineberger Symposium on “Epigenetics and Cancer”, Chapel Hill, NC, USA
- 9/24/2013 Invited Talk, the 2nd Annual Conference on “Targeting Histone Methyltransferases”, Boston, MA, USA

Below was during the trainee period

- 9/26/2011 Invited Talk, Annual symposium of Starr Foundation Cancer Consortium, Cold Spring Harbor, NY
- 6/16/2009 Talk Selected from Abstracts, the 2009 FASEB Conference on “Epigenetics, Chromatin and Transcription”, Snowmass, CO
- 1/6/2008 Invited Talk, the 2nd Genetic Society of America (GSA) Meeting on “Model Organisms & Human Biology”, San Diego, CA
- 12/12/2005 Talk Selected from Abstracts, the 47th Annual Meeting of the American Society of Hematology (ASH), Atlanta, GA

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

- Pending 2021 Invited Seminar, Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA
- Pending 2021 Invited Seminar, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND

Pending 2021 Invited Seminar, Department of of Molecular and Cellular Biology, Center for Precision Environmental Health, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

5/14/2019 Invited Seminar, Department of Biochemistry and Molecular Medicine & Program in Epigenetics and Regulation, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

5/7/2019 Invited Seminar, Department of Biochemistry, Albert Einstein College of Medicine (AECOM), Bronx, NY

4/12/2019 Invited Seminar, Distinguished Scholars Seminar Series, Hackensack Meridian Health Center for Discovery and Innovation (HMH-CDI) & HMH Cancer Center, Nutley, NJ

4/1/2019 Invited Seminar, Winthrop P. Rockefeller Cancer Institute and Department of Biochemistry & Molecular Biology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR

2/19/2019 Invited Seminar, Hematologic Malignancies and Cellular Therapies Program, Duke Cancer Institute, Duke University Medical Center, Durham, NC

3/19/2018 Invited Seminar, Laboratory of Chromatin and Gene Expression, NIH/NIEHS, Research Triangle Park, NC

11/13/2017 Invited Seminar, Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

6/26/2017 Invited Seminar, Departments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY

5/22/2017 Invited Seminar, Cancer Research UK Edinburgh Centre, MRC Centre for Regenerative Medicine and MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, Scotland, UK

5/15/2017 Invited Seminar Series in Epigenetics, Dept. of Pathology & Yale Cancer Center, Yale Medical School, New Haven, CT

4/12/2017 Invited Seminar, Dept. of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX

11/7/2016 Invited Seminar, Dept. of Biochemistry & Molecular Genetics (BMG) Red Banner Seminar Series, University of Alabama at Birmingham (UAB), Birmingham, AL

6/13/2014 Invited Seminar, Moffitt Cancer Center and University of South Florida (USF), Tampa, FL

2/19/2014 Invited Seminar, Institute of Experimental Cancer Research, University of Ulm, Ulm, Germany

9/16/2013 Invited seminar, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

11/8/2012 Invited Seminar, Section on Chromatin and Gene Expression, NIH/NIEHS, Research Triangle Park, NC

10/23/2012 Invited Seminar, Dept. of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, NC

Below was during the trainee period

- 6/14/2011 Invited Seminar, Dept. of Biochemistry & Molecular Medicine, University of California at Davis School of Medicine, Sacramento, CA
- 4/6/2011 Invited Seminar, Division of Hematology & Oncology, Children's Hospital Boston, Boston, MA
- 3/3/2011 Invited Seminar, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 2/22/2011 Invited Seminar, Dept. of Molecular & Cellular Biology, UC Berkeley, CA
- 2/14/2011 Invited Seminar, Dept. of Pharmacology & Cancer Biology, Duke University, Durham, NC
- 2/8/2011 Invited Seminar, Dept. of Biological Chemistry, University of Michigan at Ann Arbor, MI
- 1/27/2011 Invited Seminar, Skirball Institute, Developmental Genetics, New York University, NY
- 1/24/2011 Invited Seminar, Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, NY, NY
- 1/19/2011 Invited Seminar, Department of Molecular Biology and Green Center of Reproductive Biology, UT Southwestern Medical Center, Dallas, TX
- 1/11/2011 Invited Seminar, Dept. of Developmental Biology, Washington University, St Louis, MO
- 12/6/2010 Invited Seminar, Dept. of Cell Biology & Anatomy, University of California at Davis, Davis, CA
- 11/18/2010 Invited Seminar, Dept. of Biomolecular Chemistry and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI
- 11/9/2010 Invited Seminar, Dept. of Molecular & Cellular Oncology, M.D. Anderson Cancer Center, Houston, TX
- 9/29/2010 Invited Seminar, Dept. of Therapeutic Radiology, Yale School of Medicine, New Haven, CT
- 9/16/2010 Invited Seminar, Ontario Cancer Institute and University of Toronto, Toronto, Canada
- 2/19/2010 Invited Seminar, Wells Center for Pediatric Research, Indiana University-Purdue University at Indianapolis (IUPUI) School of Medicine, Indianapolis, IN

INVITED PRESENTATIONS – CAMPUS-WIDE

- 12/11/2020 Interest Group Seminar, UNC Leukemia Clinic, UNC at Chapel Hill, NC
- 2/14/2020 Presentation with award of 2019 UNC's Yang Biomedicine Scholar Awardees, Chapel Hill, NC

- 11/4/2019 Presentation with award of 2019 UNC's Hettleman Prize, University Research Week, Chapel Hill, NC
- 3/7/2019 Interest Group Seminar, Carolina Chromatin Consortium (C3), Chapel Hill, NC
- 6/12/2018 Junior Faculty Forum, UNC Lineberger Comprehensive Cancer Center, NC
- 11/2/2017 Interest Group Seminar, UNC Leukemia Clinic, UNC at Chapel Hill, NC
- 10/10/2017 Scientific Retreat, UNC Lineberger Comprehensive Cancer Center, UNC at Chapel Hill, NC
- 12/1/2016 Interest Group Seminar, Carolina Chromatin Consortium (C3), Chapel Hill, NC
- 5/19/2016 Interest Group Seminar, UNC Lymphoma Group, UNC at Chapel Hill, NC
- 5/7/2016 Interest Group Seminar, Carolina Chromatin Consortium (C3), Chapel Hill, NC
- 12/1/2014 Annual Dept. Retreat Talk, Cell Biology & Molecular Therapeutics Programs, UNC Cancer Center Cancer, Chapel Hill, NC
- 10/28/2012 Annual Dept. Retreat Talk, UNC Dept. of Biochemistry & Biophysics, Wilmington, NC